You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

PLENDIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Plendil, and when can generic versions of Plendil launch?

Plendil is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in PLENDIL is felodipine. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the felodipine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Plendil

A generic version of PLENDIL was approved as felodipine by GLENMARK PHARMS LTD on December 17th, 2010.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PLENDIL?
  • What are the global sales for PLENDIL?
  • What is Average Wholesale Price for PLENDIL?
Summary for PLENDIL
Drug patent expirations by year for PLENDIL
Recent Clinical Trials for PLENDIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lawson Health Research InstitutePhase 1
Ranbaxy Laboratories LimitedN/A
LanZhou UniversityPhase 4

See all PLENDIL clinical trials

US Patents and Regulatory Information for PLENDIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-004 Sep 22, 1994 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-001 Jul 25, 1991 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-002 Jul 25, 1991 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PLENDIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-004 Sep 22, 1994 ⤷  Sign Up ⤷  Sign Up
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-001 Jul 25, 1991 ⤷  Sign Up ⤷  Sign Up
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-002 Jul 25, 1991 ⤷  Sign Up ⤷  Sign Up
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-002 Jul 25, 1991 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PLENDIL

See the table below for patents covering PLENDIL around the world.

Country Patent Number Title Estimated Expiration
German Democratic Republic 144667 VERFAHREN ZUR HERSTELLUNG VON 2,6-DIMETHYL-4-PHENYL-1,4-DIHYDROPYRIDIN-3,5-DICARBONSAEUREDIESTERN ⤷  Sign Up
Ireland 59419 New pharmaceutical preparations with extended release ⤷  Sign Up
Sweden 8303617 ⤷  Sign Up
Czechoslovakia 270560 METHOD OF BIOLOGICALLY ACTIVE COMPOUNDS SOLUBILIZATION ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PLENDIL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0007293 95C0001 Belgium ⤷  Sign Up PRODUCT NAME: FELODIPINE, METOPOLOL SUCCINATE; NAT. REGISTRATION NO/DATE: 122 IS 160 F 3 / 19921230; FIRST REGISTRATION: DK 8678 19921230
0265685 SPC/GB98/047 United Kingdom ⤷  Sign Up PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
0265685 C980030 Netherlands ⤷  Sign Up PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
0007293 SPC/GB93/134 United Kingdom ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.